NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NVCR NovoCure

Market Closed 04-17 16:00:00 EDT

12.83

+0.21

+1.66%

盘后12.93

+0.10+0.78%

18:18 EDT

High13.17	Low12.78	Vol1.40M
Open12.99	D1 Closing12.62	Amplitude3.13%
Mkt Cap1.46B	Tradable Cap1.21B	Total Shares114.00M
T/O18.08M	T/O Rate1.49%	Tradable Shares94.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NVCR","market":"US","secType":"STK","nameCN":"NovoCure","latestPrice":12.83,"timestamp":1776456000000,"preClose":12.62,"halted":0,"volume":1401992,"hourTrading":{"tag":"盘后","latestPrice":12.93,"preClose":12.83,"latestTime":"18:18 EDT","volume":36104,"amount":463265.544231,"timestamp":1776464313945,"change":0.1,"changeRate":0.007794,"amplitude":0.007794},"delay":0,"changeRate":0.01664025356576869,"floatShares":94147892,"shares":113999999,"eps":-1.222073,"marketStatus":"Market Closed","change":0.21,"latestTime":"04-17 16:00:00 EDT","open":12.99,"high":13.17,"low":12.775,"amount":18078082.581448,"amplitude":0.0313,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.222073,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776672000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1443758400000,"exchange":"NASDAQ","adjPreClose":12.62,"preHourTrading":{"tag":"盘前","latestPrice":12.7235,"preClose":12.62,"latestTime":"09:14 EDT","volume":72,"amount":913.957488,"timestamp":1776431698851,"change":0.1035,"changeRate":0.008201,"amplitude":0.008201},"postHourTrading":{"tag":"盘后","latestPrice":12.93,"preClose":12.83,"latestTime":"18:18 EDT","volume":36104,"amount":463265.544231,"timestamp":1776464313945,"change":0.1,"changeRate":0.007794,"amplitude":0.007794},"volumeRatio":1.1320441799075238,"impliedVol":0.8347,"impliedVolPercentile":0.744},"requestUrl":"/m/hq/s/NVCR","defaultTab":"news","newsList":[{"id":"1193168237","title":"Earning Preview: NovoCure this quarter’s revenue is expected to increase by 14.50%, and institutional views are cautious","url":"https://stock-news.laohu8.com/highlight/detail?id=1193168237","media":"Earnings Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1193168237?lang=en_us&edition=fundamental","pubTime":"2026-04-13 08:59","pubTimestamp":1776041953,"startTime":"0","endTime":"0","summary":"Abstract NovoCure will report its first-quarter 2026 financial results on April 20, 2026 Pre-Market, with investor attention centered on mid-teens revenue growth, sustained gross margin efficiency,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: NovoCure this quarter’s revenue is expected to increase by 14.50%, and institutional views are cautious","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627216466","title":"Novocure Price Target Maintained With a $18.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2627216466","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627216466?lang=en_us&edition=fundamental","pubTime":"2026-04-16 21:43","pubTimestamp":1776346980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NVCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2026 09:43 ET (13:43 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4588","BK4082","BK4585","BK4548","NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627153872","title":"NovoCure (NVCR) Gets a Hold from Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2627153872","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627153872?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:45","pubTimestamp":1776343549,"startTime":"0","endTime":"0","summary":"Wedbush analyst maintained a Hold rating on NovoCure today and set a price target of $18.00. Currently, the analyst consensus on NovoCure is a Stro...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/novocure-nvcr-gets-a-hold-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/novocure-nvcr-gets-a-hold-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","BK4585","BK4548","BK4082","BK4588","NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627287804","title":"Tango Therapeutics names Matthew Gall CFO, replacing Daniella Beckman","url":"https://stock-news.laohu8.com/highlight/detail?id=2627287804","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627287804?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:06","pubTimestamp":1776258417,"startTime":"0","endTime":"0","summary":"Tango Therapeutics appointed Matthew Gall as chief financial officer effective April 15, replacing Daniella Beckman.Gall previously served as CFO at Kalaris Therapeutics, CFO at iTeos Therapeutics, held finance, business development, corporate strategy roles at Sarepta Therapeutics, Celgene, Gilead Sciences.Yen-Ching Chua named chief development operations officer effective June 1 to oversee clinical operations, data management, quality, clinical compliance, clinical sourcing.Chua previously led clinical and development operations at Novocure, Debiopharm International, MorphoSys, Novartis.Janice Kapty appointed SVP, corporate strategy and project leadership effective April 15, with prior drug development leadership roles at Arvinas, MorphoSys, Constellation Pharmaceuticals, Bristol Myers Squibb, Celgene.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL71jQj5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","IE00BZ1G4Q59.USD","TNGX","BK4581","LU2242652126.USD","IE0009355771.USD","LU1934455194.USD","LU1261432733.SGD","IE00BGHQF748.EUR","LU0289739699.SGD","LU1074936037.SGD","LU1718418525.SGD","LU0234570918.USD","LU1839511570.USD","LU0122379950.USD","NDAQ","LU1674673428.USD","BK4550","IE00BSNM7G36.USD","LU2087621335.USD","IE00B3T34201.USD","LU0321505868.SGD","LU0868494617.USD","LU2210149790.SGD","SG9999014013.SGD","LU0320765992.SGD","SG9999014021.USD","IE00B7SZLL34.SGD","IE00BFXG1179.USD","LU2468319806.SGD","LU1066053197.SGD","LU1983299246.USD","GILD","IE00B64PRP62.GBP","LU1670711123.USD","NVCR","ARVN","SG9999015986.USD","LU1868836591.USD","LU0823416689.USD","LU0889565916.HKD","IE00BN0W2T93.GBP","LU1066051498.USD","BMY","BK4082","IE00B3QW5Z07.USD","LU1674673691.USD","LU1057294990.SGD","LU1868837136.USD","LU0965509101.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627964466","title":"Assessing NovoCure (NVCR) Valuation After Prolonged Share Price Weakness And Undervalued Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2627964466","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627964466?lang=en_us&edition=fundamental","pubTime":"2026-04-14 03:14","pubTimestamp":1776107685,"startTime":"0","endTime":"0","summary":"NovoCure (NVCR) has been drawing attention after recent trading left the share price at US$10.58. Year to date and 1-year total returns are approximately 19% and 36% declines, respectively.\nSee our latest analysis for NovoCure.\nThe share price has been under pressure, with a 30 day share price return of 12.27% and a 90 day decline of 22.49%. At the same time, the 1 year total shareholder return of 36.07% and 5 year total shareholder return of 94.46% point to sustained weakness, suggesting...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/assessing-novocure-nvcr-valuation-after-prolonged-share-pric-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/assessing-novocure-nvcr-valuation-after-prolonged-share-pric-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4585","NVCR","BK4534","BK4082","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626153105","title":"NovoCure Expands Executive Role, Adjusts CMO Compensation","url":"https://stock-news.laohu8.com/highlight/detail?id=2626153105","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626153105?lang=en_us&edition=fundamental","pubTime":"2026-04-10 05:32","pubTimestamp":1775770375,"startTime":"0","endTime":"0","summary":"NovoCure ( ($NVCR) ) has issued an announcement. On April 8, 2026, NovoCure Limited adjusted the compensation of senior executive Uri Weinberg, M.D...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novocure-expands-executive-role-adjusts-cmo-compensation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novocure-expands-executive-role-adjusts-cmo-compensation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","BK4585","BK4588","BK4548","BK4082","NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626580341","title":"Novocure pays CHF 5,000 monthly stipend for interim chief medical officer role","url":"https://stock-news.laohu8.com/highlight/detail?id=2626580341","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626580341?lang=en_us&edition=fundamental","pubTime":"2026-04-10 05:05","pubTimestamp":1775768702,"startTime":"0","endTime":"0","summary":"Novocure set new pay terms for Uri Weinberg tied to expanded duties as Chief Medical Officer while continuing as Chief Innovation Officer.Weinberg will receive monthly stipend of CHF 5,000 for duration of assignment.Stipend will be excluded from calculations for annual incentive payment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL2PgWB0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4548","BK4588","BK4534","NVCR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625797976","title":"Novocure price target lowered to $16 from $23 at Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2625797976","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625797976?lang=en_us&edition=fundamental","pubTime":"2026-04-06 20:12","pubTimestamp":1775477543,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Novocure (NVCR) to $16 from $23 and keeps an Outperform rating on the shares as...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novocure-price-target-lowered-to-16-from-23-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novocure-price-target-lowered-to-16-from-23-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4548","BK4082","BK4585","NVCR","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624328976","title":"NovoCure (NVCR) Jumps After Strong PANOVA-4 Data Validates TTFields Combo Potential In Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2624328976","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624328976?lang=en_us&edition=fundamental","pubTime":"2026-04-03 11:32","pubTimestamp":1775187154,"startTime":"0","endTime":"0","summary":"In late March 2026, Novocure reported that its Phase 2 PANOVA-4 trial showed Tumor Treating Fields therapy combined with atezolizumab and gemcitabine/nab-paclitaxel achieved a statistically significant improvement in disease control for first-line metastatic pancreatic ductal adenocarcinoma versus historical chemotherapy controls, with tolerability consistent with prior TTFields studies.\nThis outcome underscores how pairing TTFields with immunotherapy and chemotherapy could expand the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/novocure-nvcr-jumps-after-strong-panova-4-data-validates-ttf","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/novocure-nvcr-jumps-after-strong-panova-4-data-validates-ttf","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4534","NVCR","BK4588","BK4548","AIPO","BK4585","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624971115","title":"Novocure to report first-quarter results, host conference call and webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2624971115","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624971115?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:00","pubTimestamp":1775041224,"startTime":"0","endTime":"0","summary":"Novocure scheduled first-quarter 2026 financial results release for April 30, 2026, before U.S. markets open.Management set conference call and webcast for 8:00 a.m. EDT on April 30, 2026.Investor Relations page to host slides and corporate presentation at .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire  on April 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL5pMNs6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4082","BK4548","BK4588","NVCR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624597650","title":"Novocure to Report First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2624597650","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624597650?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:00","pubTimestamp":1775041200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUA842SPY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4534","BK4585","BK4082","NVCR","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624591045","title":"Zymeworks appoints Kristin Stafford as CFO effective April 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2624591045","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624591045?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:00","pubTimestamp":1775037630,"startTime":"0","endTime":"0","summary":"Zymeworks appointed Kristin Stafford as chief financial officer, effective April 1, 2026.Stafford most recently served as senior vice president, chief accounting officer at Royalty Pharma, a role she held since December 2018.Her earlier posts include vice president, finance at Royalty Pharma and CFO at BioPharma Credit from 2016 to 2018.She previously worked at Ernst & Young in London on U.S. capital markets transactions for European life sciences companies.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL316FHs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","ZYME","RPRX","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","BK4534","BK4585","LU0314104364.USD","NVCR","BK4082","IE00BN0W2W23.USD","LU2095319765.USD","BK4007","BK5078","IE00B64PRP62.GBP","BPCR.UK","BK4139","BK4588","IE00BN0W2V16.EUR","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","NDAQ","SG9999014021.USD","BK4548","SG9999014005.SGD","IE00BGHQF748.EUR","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622385001","title":"Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Ongoing Middle East Tensions","url":"https://stock-news.laohu8.com/highlight/detail?id=2622385001","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622385001?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:56","pubTimestamp":1774529760,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.8% and the actively traded Invesco QQQ Trust (QQQ) retreated 1% in Thursday's premarket activity amid ongoing tensions in ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RTH","XLK","VDC","OLPX","XSD","FAZ","XRT","FAS","BITO","HUBG","XLF","EEM","EQR","VIS","GLNG","IYJ","VHT.AU","IGV","XLP","IYK","RTH.AU","SOXX","EXI","SPY.AU","QQQ","VHT","IGM","EETH","CRBG","IPK","EQH","SMCI","GLD","XLI","BETH","IVV","SLV","UNG",".IXIC","NVCR","IYH","IYE","SPY","IYW","IBB","USO",".DJI","XLE","XLY","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622685907","title":"Novocure reports PANOVA-4 primary endpoint met; disease control rate rises to 74.4% from 48% in historical control","url":"https://stock-news.laohu8.com/highlight/detail?id=2622685907","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622685907?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522835,"startTime":"0","endTime":"0","summary":"Novocure reported positive topline results from the Phase 2 PANOVA-4 trial evaluating Tumor Treating Fields  therapy with atezolizumab plus gemcitabine and nab-paclitaxel as first-line treatment for metastatic pancreatic ductal adenocarcinoma.The trial met its primary endpoint, with a disease control rate of 74.4% in the TTFields combination group  versus 48% in a historical control from the MPACT study .Secondary results included an objective response rate of 34.6% and a median overall survival of 9.7 months.Novocure said additional PANOVA-4 results will be presented at a future scientific forum.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL3ynhqh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4548","BK4588","BK4534","NVCR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622851852","title":"Novocure Ltd - Ttfields Therapy Well-Tolerated With Device Safety Consistent With Prior Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851852","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622851852?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUA2HLZKL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4082","NVCR","BK4548","BK4585","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622851375","title":"Novocure Announces Positive Topline Results From Phase 2 Panova-4 Clinical Trial of Tumor Treating Fields (Ttfields) Therapy for Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622851375?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUA2HLZKL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","BK4082","BK4548","BK4588","NVCR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622585139","title":"Novocure Ltd - Panova-4 Meets Primary Endpoint With Dcr of 74.4% VS 48% in Historical Control","url":"https://stock-news.laohu8.com/highlight/detail?id=2622585139","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622585139?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUA2HLZKL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","BK4548","NVCR","BK4082","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618604979","title":"Should Japan’s Optune Lua Reimbursement Win Reframe NovoCure’s (NVCR) Access and Utilization Story?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618604979","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618604979?lang=en_us&edition=fundamental","pubTime":"2026-03-10 09:15","pubTimestamp":1773105311,"startTime":"0","endTime":"0","summary":"In early March 2026, NovoCure reported that Japan’s Ministry of Health, Labour and Welfare approved National Health Insurance reimbursement for Optune Lua for adults with unresectable advanced or recurrent non-small cell lung cancer progressing after platinum-based chemotherapy.\nThis milestone not only broadens access to NovoCure’s Tumor Treating Fields technology in a key oncology market, but also adds a new reimbursed indication to support its growing therapy ecosystem.\nNext, we’ll explore...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/should-japans-optune-lua-reimbursement-win-reframe-novocures","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/should-japans-optune-lua-reimbursement-win-reframe-novocures","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4548","NVCR","BK4534","BK4588","BK4585","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616350754","title":"NovoCure (NVCR) Is Up 24.5% After FDA Approval Of Optune Pax And 2026 Guidance Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2616350754","media":"Simply Wall St.","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616350754?lang=en_us&edition=fundamental","pubTime":"2026-03-03 00:20","pubTimestamp":1772468424,"startTime":"0","endTime":"0","summary":"In late February 2026, NovoCure reported fourth-quarter 2025 revenue of US$174.35 million and a quarterly loss of US$24.5 million, alongside full-year 2025 revenue of US$655.35 million and a narrowed annual loss of US$136.23 million, while issuing 2026 net revenue guidance of US$675 million to US$705 million.\nAlongside these results, NovoCure secured U.S. FDA approval and began the commercial launch of Optune Pax for locally advanced pancreatic cancer, signaling a shift from a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/novocure-nvcr-is-up-245-after-fda-approval-of-optune-pax-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/novocure-nvcr-is-up-245-after-fda-approval-of-optune-pax-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4534","NVCR","BK4082","BK4588","BK4585","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616339084","title":"Japan approves national reimbursement for Novocure's Optune Lua in NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2616339084","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616339084?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:00","pubTimestamp":1772452830,"startTime":"0","endTime":"0","summary":"Novocure Ltd. said Japan’s Ministry of Health, Labour and Welfare approved national reimbursement for Optune Lua under the country’s National Health Insurance coverage. The device is approved in Japan for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced or recurrent non-small cell lung cancer who progressed on or after platinum-based chemotherapy. Novocure said it plans to launch Optune Lua in Japan with reimbursement coverage.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL9CqkmH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4585","BK4588","NVCR","BK4082","BK4548"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novocure.com","stockEarnings":[{"period":"1week","weight":0.2127},{"period":"1month","weight":0.0638},{"period":"3month","weight":-0.0594},{"period":"6month","weight":-0.0689},{"period":"1year","weight":-0.1765},{"period":"ytd","weight":-0.0077}],"compareEarnings":[{"period":"1week","weight":0.0452},{"period":"1month","weight":0.0736},{"period":"3month","weight":0.0267},{"period":"6month","weight":0.0689},{"period":"1year","weight":0.349},{"period":"ytd","weight":0.0414}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.272727,"avgChangeRate":-0.026321},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.001726},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.034505},{"month":4,"riseRate":0.545455,"avgChangeRate":0.088417},{"month":5,"riseRate":0.8,"avgChangeRate":0.134604},{"month":6,"riseRate":0.4,"avgChangeRate":-0.026837},{"month":7,"riseRate":0.5,"avgChangeRate":-0.004605},{"month":8,"riseRate":0.6,"avgChangeRate":0.019977},{"month":9,"riseRate":0.4,"avgChangeRate":-0.021376},{"month":10,"riseRate":0.2,"avgChangeRate":-0.091688},{"month":11,"riseRate":0.636364,"avgChangeRate":0.077306},{"month":12,"riseRate":0.545455,"avgChangeRate":0.065178}],"exchange":"NASDAQ","name":"NovoCure","nameEN":"NovoCure"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NovoCure(NVCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NovoCure,NVCR,NovoCure股票,NovoCure股票老虎,NovoCure股票老虎国际,NovoCure行情,NovoCure股票行情,NovoCure股价,NovoCure股市,NovoCure股票价格,NovoCure股票交易,NovoCure股票购买,NovoCure股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NovoCure(NVCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}